RecombinantRabMAb

Recombinant Anti-RAB22A antibody [EPR9486] (ab137093)

Submit a review Submit a question References (8)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR9486] to RAB22A
  • Suitable for: WB, ICC/IF, IP
  • Reacts with: Mouse, Rat, Human

Overview

  • Product name

    Anti-RAB22A antibody [EPR9486]
    See all RAB22A primary antibodies

  • Description

    Rabbit monoclonal [EPR9486] to RAB22A

  • Host species

    Rabbit

  • Tested applications

    Suitable for: WB, ICC/IF, IPmore details

  • Species reactivity

    Reacts with: Mouse, Rat, Human

  • Immunogen

    Synthetic peptide within Human RAB22A aa 1-100. The exact sequence is proprietary.

  • Positive control

    • WB: MCF-7 and BxPC-3 cell lysate; fetal kidney and fetal heart tissue lysates ICC/IF: MCF-7 cells. IP: MCF-7 cells.

  • General notes

     

     

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

    Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

    We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

    In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

    We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

    Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

    Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

Properties

Applications

Our Abpromise guarantee covers the use of ab137093 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 22 kDa.
ICC/IF 1/100.

For unpurified use at 1/250 - 1/500.
IP 1/10 - 1/100.

Target

Images

  • Western blot - Anti-RAB22A antibody [EPR9486] (ab137093)
    Western blot - Anti-RAB22A antibody [EPR9486] (ab137093)
    All lanes : Anti-RAB22A antibody [EPR9486] (ab137093) at 1/1000 dilution (Purified)

    Lane 1 : MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysates
    Lane 2 : Mouse brain lysates
    Lane 3 : Rat brain lysates

    Lysates/proteins at 15 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

    Predicted band size: 22 kDa
    Observed band size: 22 kDa

  • Western blot - Anti-RAB22A antibody [EPR9486] (ab137093)
    Western blot - Anti-RAB22A antibody [EPR9486] (ab137093)
    Anti-RAB22A antibody [EPR9486] (ab137093) at 1/1000 dilution (Purified) + Human brain lysates at 15 µg

    Secondary
    Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

    Predicted band size: 22 kDa
    Observed band size: 22 kDa

  • Western blot - Anti-RAB22A antibody [EPR9486] (ab137093)
    Western blot - Anti-RAB22A antibody [EPR9486] (ab137093)
    All lanes : Anti-RAB22A antibody [EPR9486] (ab137093) at 1/1000 dilution (unpurified)

    Lane 1 : MCF-7 lysate
    Lane 2 : Fetal kidney lysate
    Lane 3 : BxPC-3 lysate
    Lane 4 : Fetal heart lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution

    Predicted band size: 22 kDa

  • Immunoprecipitation - Anti-RAB22A antibody [EPR9486] (ab137093)
    Immunoprecipitation - Anti-RAB22A antibody [EPR9486] (ab137093)

    ab137093 (purified) at 1/40 dilution (2ug) immunoprecipitating RAB22A in MCF7 whole cell lysates.
    Lane 1: MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysates 10ug
    Lane 2 (+): ab137093 & MCF7 whole cell lysates
    Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab137093 in MCF7 whole cell lysates
    For western blotting, VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/1000 dilution.
    Blocking and diluting buffer: 5% NFDM/TBST.

  • Immunocytochemistry/ Immunofluorescence - Anti-RAB22A antibody [EPR9486] (ab137093)
    Immunocytochemistry/ Immunofluorescence - Anti-RAB22A antibody [EPR9486] (ab137093)

    Immunocytochemistry/ Immunofluorescence analysis of MCF7 (Human breast adenocarcinoma epithelial cell) cells labeling RAB22A with purified ab137093 at 1/100 dilution (7.6 µg/ml). Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) at 1/200 (2.5 µg/ml) dilution. Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/1000 (2 µg/ml) dilution. DAPI (blue) was used as nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.

  • Immunocytochemistry/ Immunofluorescence - Anti-RAB22A antibody [EPR9486] (ab137093)
    Immunocytochemistry/ Immunofluorescence - Anti-RAB22A antibody [EPR9486] (ab137093)
    Immunocytochemistry/ Immunofluorescence analysis of MCF-7 cells labelling RAB22A with ab137093 (unpurified) at 1/250 dilution.
  • Anti-RAB22A antibody [EPR9486] (ab137093)
    Anti-RAB22A antibody [EPR9486] (ab137093)

References (8)

Publishing research using ab137093? Please let us know so that we can cite the reference in this datasheet.

ab137093 has been referenced in 8 publications.

  • Ivanova D  et al. CtBP1-Mediated Membrane Fission Contributes to Effective Recycling of Synaptic Vesicles. Cell Rep 30:2444-2459.e7 (2020). PubMed: 32075774
  • Tang X  et al. LncRNA ZFAS1 confers inflammatory responses and reduces cholesterol efflux in atherosclerosis through regulating miR-654-3p-ADAM10/RAB22A axis. Int J Cardiol N/A:N/A (2020). PubMed: 32349937
  • Fang Z  et al. MicroRNA-193b acts as a tumor suppressor in colon cancer progression via targeting RAB22A. Exp Ther Med 17:3921-3928 (2019). PubMed: 31007734
  • Zhang L  et al. Hypoxia preconditioned renal tubular epithelial cell-derived extracellular vesicles alleviate renal ischaemia-reperfusion injury mediated by the HIF-1a/Rab22 pathway and potentially affected by microRNAs. Int J Biol Sci 15:1161-1176 (2019). PubMed: 31223277
  • Xie JC  et al. Hypoxia increases amyloid-ß level in exosomes by enhancing the interaction between CD147 and Hook1. Am J Transl Res 10:150-163 (2018). PubMed: 29423001
  • Yang YN  et al. miR-204 reverses temozolomide resistance and inhibits cancer initiating cells phenotypes by degrading FAP-a in glioblastoma. Oncol Lett 15:7563-7570 (2018). PubMed: 29725461
  • Yang F  et al. An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer. Cell Death Differ 25:2209-2220 (2018). PubMed: 29844570
  • Yao Y  et al. A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity. Elife 4:N/A (2015). ICC/IF . PubMed: 25738228

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

There are currently no Customer reviews or Questions for ab137093.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com